Published on 19 Apr 2024 on Zacks via Yahoo Finance
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path Holdings, Inc. BPTH announced that it has completed the second dose cohort in the dose-escalation portion of an early-stage study evaluating its investigational candidate, BP1002, for the treatment of refractory/relapsed (R/R) acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
The novel AML therapy, BP1002, is being developed by leveraging Bio-Path’s proprietary DNAbilize antisense RNAi nanoparticle technology. Per the company, BP1002 targets the Bcl-2 protein, which is responsible for driving cell survival in up to 60% of all cancers.